Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide.
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Kiniksa Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KNSA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: KNSA underperformed the US Biotechs industry which returned -0.6% over the past year.
Return vs Market: KNSA underperformed the US Market which returned -14.9% over the past year.
Price Volatility Vs. Market
How volatile is Kiniksa Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWill Kiniksa Pharmaceuticals (NASDAQ:KNSA) Spend Its Cash Wisely?
6 months ago | Simply Wall StWe Think Kiniksa Pharmaceuticals (NASDAQ:KNSA) Needs To Drive Business Growth Carefully
9 months ago | Simply Wall StVolatility 101: Should Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Have Dropped 23%?
Is Kiniksa Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: KNSA ($16.84) is trading above our estimate of fair value ($9.04)
Significantly Below Fair Value: KNSA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: KNSA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: KNSA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KNSA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KNSA is overvalued based on its PB Ratio (4.1x) compared to the US Biotechs industry average (2.6x).
How is Kiniksa Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KNSA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KNSA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KNSA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if KNSA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if KNSA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KNSA is forecast to be unprofitable in 3 years.
How has Kiniksa Pharmaceuticals performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: KNSA is currently unprofitable.
Growing Profit Margin: KNSA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if KNSA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare KNSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KNSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: KNSA has a negative Return on Equity (-71.81%), as it is currently unprofitable.
How is Kiniksa Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: KNSA's short term assets ($241.6M) exceed its short term liabilities ($27.8M).
Long Term Liabilities: KNSA's short term assets ($241.6M) exceed its long term liabilities ($1.3M).
Debt to Equity History and Analysis
Debt Level: KNSA is debt free.
Reducing Debt: KNSA has not had any debt for past 5 years.
Inventory Level: KNSA has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if KNSA's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KNSA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if KNSA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Kiniksa Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KNSA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate KNSA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KNSA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KNSA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KNSA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sanj Patel (49yo)
Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals since July 2015. Before founding Kiniksa Pharmaceuticals in 2015, Mr. Patel founded Synageva BioPharma Corp. in June 2008 a ...
CEO Compensation Analysis
Compensation vs Market: Sanj's total compensation ($USD7.31M) is above average for companies of similar size in the US market ($USD3.25M).
Compensation vs Earnings: Sanj's compensation has increased whilst the company is unprofitable.
|CEO & Chairman of the Board||4.75yrs||US$7.31m||3.33% $31.1m|
|Senior VP & Chief Medical Officer||3.67yrs||US$2.50m||0.054% $505.2k|
|Principal Financial Officer & Chief Accounting Officer||0.083yr||no data||0.0021% $19.2k|
|Executive VP of Corporate Development & Operations||0.42yr||no data||0.89% $8.3m|
|Vice President of Investor Relations||no data||no data||no data|
|Vice President of of Human Resources||no data||no data||no data|
|Senior VP||no data||no data||0.73% $6.8m|
|Consultant||0.083yr||no data||0.94% $8.8m|
|Executive Vice President of Corporate Affairs||no data||no data||0.99% $9.3m|
|Senior Vice President of Program Management||no data||no data||no data|
Experienced Management: KNSA's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
|CEO & Chairman of the Board||4.75yrs||US$7.31m||3.33% $31.1m|
|Independent Director||2.17yrs||US$345.25k||no data|
|Lead Independent Director||4.5yrs||US$258.35k||0.027% $249.9k|
|Independent Director||3.33yrs||US$170.14k||no data|
|Independent Director||4.5yrs||US$166.35k||no data|
|Independent Director||1.08yrs||no data||no data|
|Independent Director||4.5yrs||US$241.72k||no data|
|Chairman of Scientific Advisory Board||no data||no data||1.67% $15.6m|
|Independent Director||2.17yrs||US$346.71k||no data|
Experienced Board: KNSA's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 82.9%.
Kiniksa Pharmaceuticals, Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Kiniksa Pharmaceuticals, Ltd.
- Ticker: KNSA
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$935.418m
- Shares outstanding: 55.55m
- Website: https://www.kiniksa.com
Number of Employees
- Kiniksa Pharmaceuticals, Ltd.
- Clarendon House
- 2 Church Street
- HM 11
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|KNSA||NasdaqGS (Nasdaq Global Select)||Yes||Class A Common Shares||US||USD||May 2018|
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company’s preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/03 02:40|
|End of Day Share Price||2020/04/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.